Skip to main content
. 2020 Oct;8(20):1305. doi: 10.21037/atm-20-5478

Figure 6.

Figure 6

Sorafenib enhanced the chemosensitivity of hepatocellular carcinoma cells to TMZ. (A) HepG2 cells were treated with TMZ and/or Sorafenib (4 and 8 µM) for 24, 48 and 72 h. Cell inhibition rate was determined by MTT assay. The experiments were repeated 3 times independently (*, P<0.05, **, P<0.01 vs. TMZ group). (B) Huh7 cells were treated with TMZ and/or Sorafenib (1 and 2 µM) for 24, 48 and 72 h. The cell inhibition rate of Huh7 cells (*, P<0.05, **, P<0.01 vs. TMZ group). (C) MHCC-97H cells were treated with TMZ and/or Sorafenib (8 and 16 µM) for 24, 48 and 72 h. The cell inhibition rate of MHCC-97H cells (*, P<0.05, **, P<0.01 vs. TMZ group). (D) SMCC-7721 cells were treated with TMZ and/or Sorafenib (2 and 4 µM) for 24, 48 and 72 h. The cell inhibition rate of SMCC-7721 cells (*, P<0.05, **, P<0.01 vs. TMZ group). TMZ, temozolomide.